Enhanced expression of cancer testis antigen genes in glioma stem cells

Molecular Carcinogenesis

Volumn 49, Issue 6, 2010, Pages 532-544

  Yawata, Toshio ^a   Nakai, Eiichi ^a   Park, Kae Chang ^a   Chihara, Takahiro ^a   Kumazawa, Ayano ^a   Toyonaga, Shinichi ^a   Masahira, Takanori ^a   Nakabayashi, Hiromichi ^a   Kaji, Takao ^a   Shimizu, Keiji ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Cancer stem cells; Cell differentiation; Epigenetics

Indexed keywords

CANCER TESTIS ANTIGEN; CANCER VACCINE; DNA; HISTONE; HLA ANTIGEN CLASS 1;

ACETYLATION; ARTICLE; CELL DIFFERENTIATION; CELL ISOLATION; CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION; GENE TARGETING; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; STEM CELL;

ACETYLATION; AGED; ANIMALS; ANTIGENS, NEOPLASM; CELL DIFFERENTIATION; CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS I; GLIOMA; HISTONES; HUMANS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PROMOTER REGIONS, GENETIC;

EID: 77952499771     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20614     Document Type: Article

References (40)

1. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 2004;23:7267-7273. (Pubitemid 39382160)
2. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401. (Pubitemid 39551674)
3. Pellegatta S, Poliani PL, Corno D, et al. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 2006;66:10247-10252.
4. Scanlan MJ, Gure AO, Jungbluth AA, et al. Cancer/testis antigens: An expanding family of targets for cancer immunotherapy. Immunol Rev 2002;188:22-32.
5. Sigalotti L, Fratta E, Coral S, et al. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′-deoxycytidine. Cancer Res 2004;64:9167-9171.
6. Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 2006;4:339-349.
7. Druesne N, Pagniez A, Mayeur C, et al. Diallyl disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis 2004;25:1227-1236.
8. Li Y, Yin W, Wang X, Zhu W, Huang Y, Yan G. Cholera toxin induces malignant glioma cell differentiation via the PKA/CREB pathway. Proc Natl Acad Sci USA 2007;104:13438-13443.
9. Chen TC, Wadsten P, Su S, et al. The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells. Cancer Biol Ther 2002;1:268-276.
10. Zhang R, Banik NL, Ray SK. Combination of all-trans retinoic acid and interferon-gamma upregulated p27(kip1) and downregulated CDK2 to cause cell cycle arrest leading to differentiation and apoptosis in human glioblastoma LN18 (PTEN-proficient) and U87MG (PTEN-deficient) cells. Cancer Chemother Pharmacol 2008;62:407-416.
11. Hsieh J, Nakashima K, Kuwabara T, Mejia E, Gage FH. Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc Natl Acad Sci USA 2004;101:16659-16664. (Pubitemid 39557769)
12. Lyssiotis CA, Walker J, Wu C, Kondo T, Schultz PG, Wu X. Inhibition of histone deacetylase activity induces developmental plasticity in oligodendrocyte precursor cells. Proc Natl Acad Sci USA 2007;104:14982-14987. (Pubitemid 47619579)
13. French HM, Reid M, Mamontov P, Simmons RA, Grinspan JB. Oxidative stress disrupts oligodendrocyte maturation. J Neurosci Res 2009;87:3076-3087.
14. Lucio-Eterovic AK, Cortez MA, Valera ET, et al. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: Class II and IV are hypoexpressed in glioblastomas. BMC Cancer 2008;8:243.
15. Riggs MG, Whittaker RG, Neumann JR, Ingram VM. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 1977;268:462-464.
16. Yoshida M, Nomura S, Beppu T. Effects of trichostatins on differentiation of murine erythroleukemia cells. Cancer Res 1987;47:3688-3691. (Pubitemid 17105709)
17. Maio M, Coral S, Fratta E, Altomonte M, Sigalotti L. Epigenetic targets for immune intervention in human malignancies. Oncogene 2003;22:6484-6488. (Pubitemid 37372328)
18. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-1080.
19. Jaenisch R, Bird A. Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat Genet 2003;33:245-254. (Pubitemid 36278835)
20. Weiser TS, Guo ZS, Ohnmacht GA, et al. Sequential 5-aza-2′- deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother 2001;24:151-161.
21. Eng LF, Rubinstein LJ. Contribution of immunohistochemistry to diagnostic problems of human cerebral tumors. J Histochem Cytochem 1978;26:513-522.
22. van der Meulen JD, Houthoff HJ, Ebels EJ. Glial fibrillary acidic protein in human gliomas. Neuropathol Appl Neurobiol 1978;4:177-190. (Pubitemid 8377038)
23. Velasco ME, Dahl D, Roessmann U, Gambetti P. Immunohistochemical localization of glial fibrillary acidic protein in human glial neoplasms. Cancer 1980;45:484-494. (Pubitemid 10169294)
24. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-5828. (Pubitemid 37187480)
25. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67-68.
26. Kurashige T, Noguchi Y, Saika T, et al. NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: Correlation with tumor grade. Cancer Res 2001;61:4671-4674.
27. Yakirevich E, Sabo E, Lavie O, Mazareb S, Spagnoli GC, Resnick MB. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res 2003;9:6453-6460.
28. Otte M, Zafrakas M, Riethdorf L, et al. MAGE-A gene expression pattern in primary breast cancer. Cancer Res 2001;61:6682-6687. (Pubitemid 32896486)
29. Wang J, Sakariassen PØ, Tsinkalovsky O, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133-positive cells. Int J Cancer 2008;122:761-768.
30. Zeppernick F, Ahmadi R, Campos B, et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008;14:123-129. (Pubitemid 351377986)
31. Hong JA, Kang Y, Abdullaev Z, et al. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 2005;65:7763-7774.
32. Cronwright G, Le Blanc K, Gotherstrom C, Darcy P, Ehnman M, Brodin B. Cancer/testis antigen expression in human mesenchymal stem cells: Down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res 2005;65:2207-2215.
33. Costa FF, Le Blanc K, Brodin B. Concise review: Cancer/testis antigens, stem cells, and cancer. Stem Cells 2007;25:707-711.
34. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: An expanding family of targets for cancer immunotherapy. Immunol Rev 2002;188:22-32.
35. Algarra I, Collado A, Garrido F. Altered MHC class I antigens in tumors. Int J Clin Lab Res 1997;27:95-102.
36. Frumento G, Franchello S, Palmisano GL, et al. Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by γIFN treatment. Tissue Antigens 2000;56:30-37.
37. Pérez M, Cabrera T, Lopez Nevot MA, et al. Heterogeneity of the expression of class I and II HLA antigens in human breast carcinoma. J Immunogenet 1986;13:247-253.
38. Cabrera T, Angustias Fernandez M, Sierra A, et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 1996;50:127-134.
39. Mammolenti M, Gajavelli S, Tsoulfas P, Levy R. Absence of major histocompatibility complex class I on neural stem cells does not permit natural killer cell killing and prevents recognition by alloreactive cytotoxic T lymphocytes in vitro. Stem Cells 2004;22:1101-1110.
40. Natali PG, Bigotti A, Nicotra MR, Viora M, Manfredi D, Ferrone S. Distribution of human class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res 1984;44:4679-4687.